Twist Bioscience (NASDAQ:TWST) SVP Sells 935 Shares

Key Points

• SVP Paula Green sold 935 shares on March 6 at an average price of $46.43 for roughly $43,412, trimming her position by 0.75% to 124,401 shares (about $5.78M); the sale was disclosed in an SEC filing.
• TWST stock dropped 6.1% to $45.40 midday with ~851,196 shares traded; the company has a market cap of $2.78 billion and a negative price-to-earnings ratio (-35.47).
• Twist reported Q results with EPS of -$0.50 (missing consensus by $0.02) and revenue of $103.7M (beating estimates), the business remains unprofitable with negative net margin/ROE, while analysts hold a consensus "Moderate Buy" and an average target of $45.88 with several firms raising targets to $50–$52.

Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) SVP Paula Green sold 935 shares of the firm's stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $46.43, for a total value of $43,412.05. Following the sale, the senior vice president directly owned 124,401 shares in the company, valued at approximately $5,775,938.43. The trade was a 0.75% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Paula Green also recently made the following trade(s):

• On Tuesday, February 3rd, Paula Green sold 1,194 shares of Twist Bioscience stock. The shares were sold at an average price of $46.58, for a total transaction of $55,616.52.
• On Monday, December 22nd, Paula Green sold 273 shares of Twist Bioscience stock. The stock was sold at an average price of $34.56, for a total transaction of $9,434.88.

Twist Bioscience Stock Down 6.1%

Shares of TWST traded down $2.93 during midday trading on Tuesday, hitting $45.40. 851,196 shares of the company's stock traded hands, compared to its average volume of 1,381,620. The company has a current ratio of 3.78, a quick ratio of 3.37 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $2.78 billion, a price-to-earnings ratio of -35.47 and a beta of 2.23. Twist Bioscience Corporation has a 1 year low of $23.30 and a 1 year high of $57.88. The firm's fifty day moving average is $43.92 and its 200-day moving average is $34.80.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its earnings results on Monday, February 2nd. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.02). The business had revenue of $103.70 million for the quarter, compared to analyst estimates of $100.32 million. Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The firm's quarterly revenue was up 16.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Hedge Funds Weigh In On Twist Bioscience

A number of institutional investors have recently modified their holdings of the stock. Axxcess Wealth Management LLC purchased a new stake in shares of Twist Bioscience in the fourth quarter worth about $201,000. Mercer Global Advisors Inc. ADV acquired a new position in Twist Bioscience in the fourth quarter valued at approximately $242,000. Empowered Funds LLC purchased a new stake in Twist Bioscience in the 4th quarter worth approximately $58,000. VARCOV Co. acquired a new stake in shares of Twist Bioscience during the 4th quarter worth approximately $263,000. Finally, Wellington Management Group LLP increased its holdings in shares of Twist Bioscience by 171.2% during the 4th quarter. Wellington Management Group LLP now owns 813,122 shares of the company's stock valued at $25,792,000 after purchasing an additional 513,309 shares in the last quarter.

Analyst Upgrades and Downgrades

TWST has been the subject of a number of recent analyst reports. Robert W. Baird set a $50.00 target price on shares of Twist Bioscience in a research note on Tuesday, February 3rd. Barclays boosted their price objective on shares of Twist Bioscience from $39.00 to $50.00 and gave the company an "overweight" rating in a report on Tuesday, February 3rd. TD Cowen reaffirmed a "buy" rating on shares of Twist Bioscience in a research report on Thursday, January 8th. Weiss Ratings reissued a "sell (d-)" rating on shares of Twist Bioscience in a report on Monday, December 29th. Finally, Evercore lifted their target price on Twist Bioscience from $42.00 to $52.00 and gave the stock an "outperform" rating in a report on Tuesday, February 3rd. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Twist Bioscience has a consensus rating of "Moderate Buy" and an average target price of $45.88.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist's offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.